10x Genomics, Inc. TXG
At closeNov 9, 2026, 4:44 PM EST
After hours · Nov 9, 4:44 PM ET
- YTD
- +298.84%
- 1 year
- +326.56%
- Market cap
- 8.56B
- Revenue (ttm)
- 618.58M
- Profit margin
- -10.84%
- EPS (ttm)
- -0.52
- Shares out
- 121.46M
- Forward P/E
- 750.55
- YTD return
- +298.84%
- 1-year return
- +326.56%
- Volume
- 2.77M
- Avg volume
- 3.48M
- Open
- 59.97
- Previous close
- 59.28
- Day's range
- 59.46 – 66.45
- 52-week range
- 15.12 – 102.81
- Beta
- 2.03
- Analysts
- Buy
- Price target
- 68.50 (+5.3%)
- Earnings date
- Feb 11, 2027
5D -0.74 (-1.14%)
Key statistics
- Enterprise value
- 7.30B
- PEG ratio
- 0.00
- Price / sales
- 13.83
- Price / book
- 10.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1.10%
- Free cash flow
- 122.82M
- Total cash
- 575.68M
- Total debt
- 75.79M
- Return on equity
- -8.27%
- Short % of float
- 14.33%
- 50-day average
- 73.95
- 200-day average
- 41.58
Analyst view
Consensus: buy
- Target (low)
- 50.00
- Target (mean)
- 68.50
- Target (high)
- 100.00
- Strong buy1
- Buy5
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate -0.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | -0.18 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.267 | -0.15 | +0.12 | +43.82% |
| Aug 6, 2026 | Jun 30, 2026 | -0.24308 | -0.14 | +0.10 | +42.41% |
| May 7, 2026 | Mar 31, 2026 | -0.29 | -0.10 | +0.19 | +65.52% |
| Feb 12, 2026 | Dec 31, 2025 | -0.19 | -0.13 | +0.06 | +31.58% |
| Nov 6, 2025 | Sep 30, 2025 | -0.07 | -0.22 | -0.15 | -214.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | JP Morgan | main | Neutral | Neutral |
| Nov 9, 2026 | Barclays | main | Overweight | Overweight |
| Nov 6, 2026 | UBS | main | Neutral | Neutral |
| Nov 6, 2026 | Citigroup | main | Neutral | Neutral |
| Nov 6, 2026 | Stifel | main | Buy | Buy |
| Oct 13, 2026 | TD Cowen | main | Hold | Hold |
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- 10xgenomics.com
News
JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65 
Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70 
What Torex Gold Resources (TXG) Said on Its Q3 Earnings Call - UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61
- Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60
What 10x Genomics (TXG) Said on Its Q3 Earnings Call 
Stifel Maintains Buy on 10x Genomics, Raises Price Target to $68 
10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est 
Torex Gold Resources (TSE:TXG) Share Price Crosses Above 200-Day Moving Average – Here’s Why 
10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
Your note
Sign in to keep a note on TXG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HINDSON BENJAMIN J | President | Sale | Aug 23, 2026 | 488,182 |
| KOSARAJU SRIDHAR | Director | Stock Award(Grant) | Jun 3, 2026 | 68,278 |
| MATEO ALAN V. | Director | Stock Award(Grant) | Jun 3, 2026 | 85,877 |
| POPOVITS KIMBERLY J | Director | Stock Award(Grant) | Jun 3, 2026 | 37,445 |
| SAXONOV SERGE WILSON | Chief Executive Officer | Sale | Sep 21, 2026 | 1,335,170 |
| STUELPNAGEL JOHN R | Director | Sale | Sep 2, 2026 | 328,436 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.67% | 17,629,266 | 1.15B | Jun 29, 2026 |
| Blackrock Inc. | 8.99% | 10,804,070 | 702.80M | Jun 29, 2026 |
| ARK Investment Management, LLC | 8.32% | 10,003,057 | 650.70M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.81% | 6,982,492 | 454.21M | Jun 29, 2026 |
| Quantinno Capital Management, LP | 4.55% | 5,469,698 | 355.80M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.23% | 5,082,594 | 330.62M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.94% | 3,528,683 | 229.54M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.62% | 3,148,101 | 204.78M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.52% | 3,032,629 | 197.27M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.12% | 2,548,523 | 165.78M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.08% | 2,498,429 | 162.52M | Sep 29, 2026 |
| Fidelity Select PORT.s-Select Medical Technology and Devices PORT. | 1.39% | 1,670,000 | 108.63M | Sep 29, 2026 |